CMS will be changing reimbursement practices regardless of how healthcare reform plays out
Rita Numerof, PhD, Numerof & Associates, Inc.
Advertisement
Articles by Rita Numerof, PhD, Numerof & Associates, Inc.
The most basic impulse behind CER is the desire to control healthcare costs. The implications for the biopharma industry could be significant
Advertisement
Latest Updated Articles
- Getting Ready for Comparative Effectiveness Research
August 22nd 2009
- Follow the Money... Where Healthcare Policy is Headed
April 10th 2010
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How the US Section 301 Probe Targets Germany's Drug Pricing
2
Philip Sclafani: Will PBM Reform Actually Lower Net Drug Costs?
3
How GLP-1 Growth and Specialty Drugs Are Driving Cost Pressure
4
Payers Want Real-World Evidence. Why Aren't They Using It?
5